
G1 Therapeutics Inc
NASDAQ:GTHX

Net Margin
G1 Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
US |
![]() |
G1 Therapeutics Inc
NASDAQ:GTHX
|
376.8m USD |
-77%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
333.9B USD |
7%
|
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 848%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
158.7B USD |
17%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
139.8B USD |
21%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.4B USD |
-9%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
127.9B AUD |
18%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59B USD |
32%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
51.1B USD |
-11%
|
G1 Therapeutics Inc
Glance View
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on G1 Therapeutics Inc's most recent financial statements, the company has Net Margin of -76.9%.